Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours. However, its use frequently causes peripheral neuropathies, neurological problems that affect the vast majority of patients. Symptoms include tingling and pain in the extremities, cramping, muscular weakness and difficulty walking, in addition to others. In severe cases, the severity of these adverse effects mandates dosage reduction, and even stopping the treatment.
This is a scheme illustrating the study that has identified variants in the CYP3A4 gene associated with paclitaxel severe neuropathy.
Maria Apellaniz-Ruiz, Mi-Young Lee, Lara Sanchez, Gerardo Gutierrez-Gutierrez, Isabel Calvo, Laura Garcia-Estevez, Maria Sereno, Jesus Garcia-Donas, Beatriz Castelo, Eva Guerra, Luis J. Leandro-Garcia, Alberto Cascon, Inger Johansson, Mercedes Robledo, Magnus Ingelman-Sundberg, Cristina Rodriguez-Antona. Clinical Cancer Research (2014). doi: 10.1158/1078-0432.CCR-14-1758